BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
Feature|Articles|October 8, 2023
- Pharmaceutical Executive: October 2023
- Volume 43
- Issue 10
Pharmaceutical Executive, October 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 3 years ago
A Blueprint for Balanceabout 3 years ago
Biopharma Stock Check: Market Review and Outlookabout 3 years ago
Securing the Safety Net in Drug Access and Supportabout 3 years ago
Obesity Drugs in the Payer Market: What to Expectabout 3 years ago
Boosting Clinical Trials and Patient Access with Payer Insightsabout 3 years ago
Are We Close to a Peak in Interest Rates?about 3 years ago
The Harms of ‘Helicopter Research’ in the Life Sciencesabout 3 years ago
The Rising Importance of Patient Advocacy Innovations in Asiaabout 3 years ago
A Fond FarewellAdvertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5